Biotechnology company Fate Therapeutics Inc announced that its current cash reserves are sufficient to sustain company operations until the end of 2027.

The company currently holds a total of $205 million in cash, cash equivalents, and various investments, providing a solid financial foundation for the subsequent development of cell therapies. This financial plan will support the company in advancing multiple preclinical and clinical stage projects, including CAR-NK and iPSC-derived cell therapies, while ensuring sustained investment during critical stages of new drug development.